Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Open Badges Research

GATA4 and DcR1 methylation in glioblastomas

Paulina Vaitkienė*, Daina Skiriutė, Kęstutis Skauminas and Arimantas Tamašauskas

Author Affiliations

Laboratory of Neurooncology and Genetics, Neuroscience Institute, Kaunas Academy of Medicine, Lithuanian University of Health Sciences, Eiveniu str. 4, Kaunas, LT, 50009, Lithuania

For all author emails, please log on.

Diagnostic Pathology 2013, 8:7  doi:10.1186/1746-1596-8-7

Published: 15 January 2013



Epigenetic silencing of tumor suppressor genes plays important role in gliomagenesis. Recently, GATA4 and DcR1 were suggested to be a tumor suppressor genes involved in tumorigenesis in various types of human cancers. However, up to now the methylation frequency of GATA4 and DcR1 genes has not been determined in glioblastoma. In this study, we investigated methylation of GATA4 and DcR1 promoters and their association with patient prognosis in glioblastoma.


Methylation status of GATA4 and DcR1 promoters was investigated by methylation specific PCR in 99 glioblastoma patients. Statistical analyses were conducted to investigate the association between clinical variables and overall survival time.


GATA4 and DcR1 were aberrantly methylated in 23.2% and 27.6% of glioblastoma tumors, but not in normal brain. GATA4 promoter hypermethylation showed significant association with patients age (p = 0.027). Relationship between genes promoter methylation and glioblastoma patient survival was not determined.


The present work demonstrated that GATA4 and DcR1 promoter hypermethylation is tumor specific event in glioblastoma but they promoter methylation cannot be considered as a prognostic marker of glioblastoma survival.

Virtual Slides

The virtual slide(s) for this article can be found here: webcite

Glioblastoma; Methylation; GATA4; DcR1